1. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
2. World Health Organization. Antimicrobial resistance. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed on July 12, 2023.
3. Merck Sharp & Dohme LLC, Rahway, NJ, USA. RECARBRIO™ (imipenem, cilastatin, and relebactam) for injection, for intravenous use, package insert. https://www.merck.com/product/usa/pi_circulars/r/recarbrio/recarbrio_pi.pdf. Accessed on July 12, 2023.
4. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa;Livermore;J Antimicrob Chemother,2013
5. Inactivation of the pseudomonas-derived cephalosporinase-3 (PDC-3) by relebactam;Barnes;Antimicrob Agents Chemother,2018